Technical Analysis for UTHR - United Therapeutics Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Flat |
Historical UTHR trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Multiple of Ten Bearish | Other | 0.24% | |
Overbought Stochastic | Strength | 0.24% | |
Down 3 Days in a Row | Weakness | 0.24% | |
Slingshot Bullish | Bullish Swing Setup | -2.12% | |
Overbought Stochastic | Strength | -2.12% | |
New 52 Week High | Strength | -2.37% | |
Upper Bollinger Band Walk | Strength | -2.37% | |
Overbought Stochastic | Strength | -2.37% | |
Upper Bollinger Band Touch | Strength | -2.37% | |
New 52 Week Closing High | Bullish | -3.06% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
60 Minute Opening Range Breakout | about 4 hours ago | |
Rose Above 10 DMA | about 4 hours ago | |
Up 1% | about 4 hours ago | |
10 DMA Resistance | about 7 hours ago | |
Down 1% | about 7 hours ago |
Get a Trading Assistant
- Earnings date: 02/24/2021
United Therapeutics Corporation Description
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Chemical Compounds Organic Compounds Hypertension Blastoma Alcohols Pulmonary Arterial Hypertension Hepatitis C Brain Cancer Pulmonary Hypertension Neuroblastoma Lung Diseases Treprostinil United Therapeutics Cac All Share Index Chronic And Life Threatening Conditions Prostacyclin Prostaglandins
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 176.31 |
52 Week Low | 75.58 |
Average Volume | 352,938 |
200-Day Moving Average | 121.42 |
50-Day Moving Average | 146.91 |
20-Day Moving Average | 159.80 |
10-Day Moving Average | 167.67 |
Average True Range | 5.11 |
ADX | 41.99 |
+DI | 33.85 |
-DI | 13.74 |
Chandelier Exit (Long, 3 ATRs ) | 160.97 |
Chandelier Exit (Short, 3 ATRs ) | 158.69 |
Upper Bollinger Band | 177.50 |
Lower Bollinger Band | 142.10 |
Percent B (%b) | 0.71 |
BandWidth | 22.15 |
MACD Line | 7.40 |
MACD Signal Line | 7.15 |
MACD Histogram | 0.2503 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 173.49 | ||||
Resistance 3 (R3) | 174.14 | 172.66 | 172.43 | ||
Resistance 2 (R2) | 172.66 | 171.04 | 172.34 | 172.08 | |
Resistance 1 (R1) | 169.90 | 170.04 | 169.16 | 169.26 | 171.73 |
Pivot Point | 168.43 | 168.43 | 168.06 | 168.10 | 168.43 |
Support 1 (S1) | 165.67 | 166.81 | 164.93 | 165.02 | 162.55 |
Support 2 (S2) | 164.19 | 165.81 | 163.87 | 162.20 | |
Support 3 (S3) | 161.43 | 164.19 | 161.85 | ||
Support 4 (S4) | 160.79 |